# Dennis Crowley

> Dennis Crowley is a Series C investor at Baxter International backing Sensor and Medical. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Baxter International](https://shizune.co/investors/profile/baxter-international)
- Total investments: 1
- Last investment: Sep 2020
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/dennis-crowley-8130a44

Dennis Crowley is a Series C investor at Baxter International focused on Sensor and Medical. Dennis Crowley

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Sensor | 1 | 100% |
| Medical | 1 | 100% |
| Biometrics | 1 | 100% |
| Health Care | 1 | 100% |
| Medical Device | 1 | 100% |

6 industries tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Medasense | Medasense (www.medasense.com) offers a breakthrough technology that enables clinicians to optimize and personalize pain control and avoid overmedicationMedasense’s flagship product, the PMD-200 with its NOL® index, is a unique platform that objectively monitors and quantifies the patient’s pain response by means of artificial intelligence and aproprietary non-invasive sensor platform. The PMD-200 is used to optimize pain management in operating rooms and critical care settings, where patients are unable to communicate – a $5B market. The company’s pipeline cloud-based solutions for clinics and home, leveraging the NOL technology, addresses an additional $15B global market.The PMD-200 is distributed in Europe exclusively by Medtronic (NYSE:MDT), is cleared for marketing also in Canada, Latin America and Australia, and enables connectivity with Philips patient monitors. Clinical studies have demonstrated its impact on patient safety and outcomes, including opioid-sparing.Medasense was founded in 2008 and based in Ramat Gan, Tel Aviv, Israel. | $18M | Series C | Sep 22, 2020 |  |

1 of 1 investments shown.

## Co-investors
- [LGL Partners](https://shizune.co/investors/profile/lgl-partners) — VC Fund, 1 deal together
- [OTV](https://shizune.co/investors/profile/olive-tree-ventures) — VC Fund, 1 deal together
- [Sabadell Venture Capital](https://shizune.co/investors/profile/sabadell-venture-capital) — VC Fund, 1 deal together

## About Baxter International

VC Fund · Deerfield, United States

Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.The company operates through three segments: BioScience, Medication Delivery, and Renal.- The BioScience segment manufacturesrecombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as biosurgery products and technologies used in adult stem-cell therapies; and vaccines.- The Medication Delivery segment manufactures intravenous solutions and administration sets; premixed drugs and drug-reconstitution systems; pre-filled vials and syringes for injectable drugs, intravenous nutrition products; infusion pumps; and inhalation anesthetics. This segment also offers products and services related to pharmacy compounding, drug formulation, and packaging technologies.- The Renal segment provides products to treat end-stage renal disease and irreversible kidney failure. This segment also offers solutions and other products for peritoneal dialysis, a home-based therapy and product for hemodialysis, which is conducted in a hospital or clinic.Baxter International Inc. has collaborations with HHD LLC, DEKA Products Limited Partnership, and DEKA Research and Development Corp. for the development of a home hemodialysis machine. It markets its products to hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors offices, clinical and medical research laboratories, and patients at home under physician supervision.The company was founded in 1931 and is headquartered in Deerfield, Illinois.

5 contacts available at Baxter International.

| Name | Title | Profile |
| --- | --- | --- |
| ​Ellen McIntosh | SVP, Associate General Counsel | https://shizune.co/investors/profile/ellen-mcintosh |
| David Ferguson | General Manager, Medication Delivery Global Business Unit | https://shizune.co/investors/profile/david-ferguson-4e16 |
| David Roman | Vice President, Strategy & FP&A | https://shizune.co/investors/profile/david-roman-3 |
| Dennis Crowley | SVP Business Development & Licensing | https://shizune.co/investors/profile/dennis-crowley-c084 |
| Giuseppe Accogli | SVP & President Global Businesses | https://shizune.co/investors/profile/giuseppe-accogli |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Dennis Crowley invest in?

Dennis Crowley invests primarily in Sensor, Medical and Biometrics startups, most often at Series C stage. Most of the 1 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Dennis Crowley last invest?

The most recent investment recorded for Dennis Crowley closed in Sep 2020. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co